Qpex Biopharma develops therapeutic agents that target antibiotic-resistant infections and viral diseases through advanced drug discovery techniques. The company focuses on providing effective treatments to combat the growing threat of infectious pathogens worldwide.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BAFounders
Product
Problem
The increasing prevalence of antimicrobial resistance (AMR) poses a significant threat to global public health, as many infections are becoming difficult or impossible to treat with existing antibiotics. This is often due to specific pathogens and resistance mechanisms that afflict smaller patient populations, making the development of effective treatments challenging. The lack of new, targeted therapeutics leaves clinicians with limited options for combating drug-resistant bacteria.
Solution
Qpex Biopharma, a Shionogi Group Company, focuses on developing novel anti-infective therapies to combat multi-drug resistance by understanding and overcoming resistance mechanisms. The company employs advanced drug discovery techniques to improve existing proven classes of drugs and identify new chemical classes that can overcome drug resistance. Qpex Biopharma aims to reverse drug resistance mechanisms and restore antibiotic potency against drug-resistant bacteria, ultimately providing targeted therapeutics for smaller patient populations.
Target Audience
The primary target audience includes patients suffering from infections caused by drug-resistant pathogens, as well as healthcare providers seeking effective treatment options for these infections.
Features
- Focus on understanding and overcoming drug resistance mechanisms in infectious diseases
- Development of novel products and strategies to combat multi-drug resistance
- Improvement of existing antibiotic classes to enhance their effectiveness
- Discovery of new chemical classes of drugs that can overcome resistance
- Reversal of drug resistance mechanisms to restore antibiotic potency
- Partnerships to accelerate the development and impact of products